| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 19.36 mm | 19.36 mm | 19.36 mm | 19.36 mm | 19.36 mm | 19.36 mm |
| Cash burn (monthly) | 122.67 k | 1.13 mm | 1.05 mm | 1.43 mm | (no burn) | 2.33 mm |
| Cash used (since last report) | 621.28 k | 5.71 mm | 5.29 mm | 7.22 mm | n/a | 11.82 mm |
| Cash remaining | 18.74 mm | 13.65 mm | 14.07 mm | 12.14 mm | n/a | 7.55 mm |
| Runway (months of cash) | 152.8 | 12.1 | 13.5 | 8.5 | n/a | 3.2 |
| 13F holders | Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 0.00 |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 Feb 25 | Palvella Therapeutics | NQSO Common Stock | Grant | Acquire A | No | No | 14.76 | 123,559 | 1.82 mm | 123,559 |
| 5 Feb 25 | Palvella Therapeutics | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 14.76 | 5,373 | 79.31 k | 5,373 |
| 5 Feb 25 | Palvella Therapeutics | NQSO Common Stock | Grant | Acquire A | No | No | 14.76 | 123,559 | 1.82 mm | 123,559 |
| 5 Feb 25 | Palvella Therapeutics | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 14.76 | 5,373 | 79.31 k | 5,373 |
| 5 Feb 25 | Palvella Therapeutics | NQSO Common Stock | Grant | Acquire A | No | No | 14.76 | 123,559 | 1.82 mm | 123,559 |
| 5 Feb 25 | Palvella Therapeutics | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 14.76 | 5,373 | 79.31 k | 5,373 |
| 5 Feb 25 | Palvella Therapeutics | NQSO Common Stock | Grant | Acquire A | No | No | 14.76 | 243,831 | 3.60 mm | 243,831 |
| 5 Feb 25 | Korenberg Matthew E | NQSO Common Stock | Grant | Acquire A | No | No | 14.76 | 123,559 | 1.82 mm | 123,559 |
| 5 Feb 25 | Korenberg Matthew E | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 14.76 | 5,373 | 79.31 k | 5,373 |
